Disease management
Everside recently scrapped plans for an IPO due to market conditions.
The latest clearance is for an algorithm that characterizes how much atrial fibrillation a patient is experiencing over time.
Researchers found three themes in their review of studies on wearables: the role of providers and potential benefits to care, driving behavior change and barriers to use.
![[Left] Ed Deng, co-founder and CEO, Health2Sync; and [Right] Claudio Longo, President, AstraZeneca Taiwan](/sites/mhn/files/styles/230x130/public/2025-07/%2528Left%2529%2520Ed%2520Deng%252C%2520Co-founder%2520and%2520CEO%2520of%2520Health2Sync%2520and%2520%2528Right%2529%2520Claudio%2520Longo%252C%2520President%2520of%2520AstraZeneca%2520Taiwan.jpg?itok=XO7M1UnC)
Health2Sync has upgraded its patient management platform to identify patients' CKD risk levels.
This marks the urinalysis and wound-care company's third 510(k) clearance.
Also, MedleyMed launches its virtual clinic concept.
It has been approved as a prescription-only software-as-a-medical device in the US.
They have so far developed AI prediction models for breast, colon, and lung cancers.
The company has received backing from the state government of Western Australia.
Happify Health chief strategy officer Chris Wasden discusses the company's partnership strategy, the business environment for digital therapeutics and how to encourage physician uptake.